Celltrion
Korea - IncheonBiotechnology
Focus: Celltrion is a South Korean biotechnology company specializing in monoclonal antibody biosimilars across immunology, oncology, and infectious diseases. The company is publicly listed and generates 68% of revenue from its lead product INFLECTRA (infliximab biosimilar).
Profile data last refreshed 9h ago · AI intelligence enriched 9h ago
Funding Stage
PUBLIC
Open Jobs
0
About Celltrion
AI assessmentNot HiringNo open roles listed right now. Follow Celltrion to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Celltrion's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
50 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$32M Part DStable
Peak
Anchor product delivering 68% of company revenue; established market leader but subject to biosimilar price compression.
Help build intelligence for Celltrion
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.